Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Elsevier e-Prints
Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach | npj Systems Biology and Applications
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
Sacubitril/valsartan in heart failure: latest evidence and place in therapy - Edgardo Kaplinsky, 2016
Mechanism of action for sacubitril/valsartan. 93 Reprinted from... | Download Scientific Diagram
Sacubitril + Valsartan (Entresto®)
Sacubitril/Valsartan in Management of Heart Failure: A Review of Safety, Efficacy and Cost-Effectiveness | Middle East Medical Portal
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control - Jelena P. Seferovic, Scott D. Solomon, Ellen W. Seely, 2020
Mechanism of action of sacubitril/valsartan [5]. Adapted with... | Download Scientific Diagram
Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action | Circulation Research